



**QUEEN'S  
UNIVERSITY  
BELFAST**

## Direct Reprogramming to Vascular Cells: A Mini-Review

Tsifaki, M., Kelaini, S., Caines, R., Yacoub, A., & Margariti, A. (2018). Direct Reprogramming to Vascular Cells: A Mini-Review. *Journal of Genetics and Cell Biology*, 1-4.  
[http://www.scitcentral.com/article.php?journal=26&article=259&article\\_title=Direct%20Reprogramming%20to%20Vascular%20Cells:%20A%20Mini-Review#tabs1](http://www.scitcentral.com/article.php?journal=26&article=259&article_title=Direct%20Reprogramming%20to%20Vascular%20Cells:%20A%20Mini-Review#tabs1)

**Published in:**

Journal of Genetics and Cell Biology

**Document Version:**

Publisher's PDF, also known as Version of record

**Queen's University Belfast - Research Portal:**

[Link to publication record in Queen's University Belfast Research Portal](#)

**Publisher rights**

Copyright 2018 the authors.

This is an open access article published under a Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

**General rights**

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [openaccess@qub.ac.uk](mailto:openaccess@qub.ac.uk).

## Direct Reprogramming to Vascular Cells: A Mini-Review

Marianna Tsifaki, Sophia Kelaini, Rachel Caines, Andrew Yacoub and Andriana Margariti\*

*\*The Wellcome-Wolfson Building, Centre for Experimental Medicine, Queen's University Belfast, BT9 7BL, UK.*

*Received June 07, 2018; Accepted July 19, 2018; Published August 22, 2018*

### ABSTRACT

Recent advances in the field of direct reprogramming have changed the way we see and study the plasticity of somatic cells. Many research groups worldwide are developing techniques with which one cell type is directly converted into another without passing through an intermediate multipotent stem cell-like state. Ectopic overexpression of transcription factors, microRNAs, epigenetic and metabolic regulators, even exosomal particles, have been proven sufficient in yielding a variety of cell types from fibroblasts, with neurons, hepatocytes, cardiomyocytes, endothelial cells and hematopoietic progenitor cells being amongst them. These studies have been an inspiration for creating new approaches in regenerative medicine, especially in the field of cardiovascular biology. Developing novel methods of regenerating the damaged myocardium and endothelium are crucial to millions of patients worldwide suffering from diabetes and cardiovascular disease. In the present study, we aim to review the progress of direct reprogramming and discuss the possible applications of this technology in regenerative therapy, disease modelling and drug discovery.

### FROM INDUCED PLURIPOTENT STEM CELLS TO DIRECT REPROGRAMMING

In 2006, Takahashi and Yamanaka [1] reported the existence of the first successful line of induced pluripotent stem cells (iPSCs) derived from mouse fibroblasts by forcing the overexpression of 4 transcription factors, *Oct4*, *Sox2*, *Klf4* and *c-Myc* (also known as OSKM or Yamanaka factors). Shortly after, iPSCs were successfully derived from other species including humans [2], rats [3] and rhesus monkeys [4]. Since then, multiple groups have developed protocols modifying the OSKM cocktail to improve efficiency and address safety challenges, resulting in the generation of well-characterised iPSCs from a variety of sources. While iPSCs are a valuable tool in regenerative medicine, the risk of tumour development makes their clinical application in humans challenging. Arguably, using iPSCs-derived cells for disease modelling, drug development and study in the lab is invaluable; for example, there are multiple protocols that efficiently produce functional cardiomyocytes and endothelial cell (EC) types. However, the safety of these cells is questioned due to the integration of foreign DNA in the human cells.

### HISTORY OF CELLULAR REPROGRAMMING

The road to pluripotency has inspired the hypothesis that, during reprogramming, there is a short window when the cell is epigenetically “fluid”. Slowly but steadily, the idea of manipulating the cell fate during this time frame excited the scientific community and, thus, attempts to directly

reprogram a somatic cell line into another commenced. In 1987, Davis et al. [5] introduced the idea of transdifferentiation from fibroblasts into myoblasts via epigenetic modulation. Even though it did not receive the same amount of attention as the reprogramming attempts to pluripotency that took place almost 20 years later, it did serve as inspiration for scientists. At this point, it is very important to note that during these years the idea was not forgotten or ostracised. There are multiple publications - some of them now retracted - claiming that during embryogenesis blood cells turn into neurons or hepatic cells but these claims were never reproduced so the idea of direct reprogramming was very hard to be accepted [6]. The OSKM reprogramming was the catalyst of a revolution in the field that resulted in hundreds of publications tweaking

**Corresponding author:** Dr. Andriana Margariti, PhD, Queen's University Belfast, Centre for Experimental Medicine Wellcome - Wolfson Building 97 Lisburn Road, BT9 7BL, UK, Tel: 0044 028 9097 6476; E-mail: a.margariti@qub.ac.uk

**Citation:** Tsifaki M, Kelaini S, Caines R, Yacoub A & Margariti A. (2018) Direct Reprogramming to Vascular Cells: A Mini-Review. J Genet Cell Biol, 1(1): 13-16.

**Copyright:** ©2018 Tsifaki M, Kelaini S, Caines R, Yacoub A & Margariti A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

and twisting every little aspect of the original idea so that the generation of therapeutic cells becomes a reality.

### PARTIAL REPROGRAMMING

Moving forward, in 2011 reports of successful conversion of mouse fibroblasts into neural progenitors [7] revived the interest and in 2012 the idea of a short partial reprogramming was introduced, in which the cells bypassed the intermediate multipotent state and were directed towards fully functional ECs [8] that had high angiogenic ability both in vivo and in vitro. A year later, human smooth muscle cells (SMCs) were generated through the partially-induced pluripotent stem (PiPS) cells technology [9]. The combination of PiPS-ECs and PiPS-SMCs in vascular grafts was reported to increase the survival of SCID mice [9] in vivo and create a very promising mode of studying cardiovascular disease in vitro [10-12].

The protocols kept evolving and shortly only two or even one, out of the four OSKM factors was enough to reprogram fibroblasts towards an EC fate. Li et al. [13] generated functional human ECs in a month using only Oct4 and Klf4 while murine fibroblasts were directed into an EC fate using only Oct4 and small molecules [14].

### REFINING THE DIRECT REPROGRAMMING APPROACH TO IMPROVE EFFICIENCY

Additional approaches towards more effective reprogramming have also been examined, with the OSKM factors left out in favour of transcription factors that are specific to the endpoint cell line [15]. For example, Ieda et al. [16] showcased the conversion of human fibroblasts into cardiomyocytes with Gata4, Mef2c and Tbx5 (GMT) and Han et al. [17] into endothelial cells with Foxo1, Er71, Klf2, Tal1 and Lmo2 [17]. However, in both cases the efficiency was quite low (5%). This led to trying out even more combinations where, for example, the addition of Hand2 and NK2 homeobox 5 (Nkx2.5) achieved a 50-fold increase in efficiency compared to GMT alone [18]. Other combinational strategies evaluated specific miRNAs (miR-1, miR-133, miR-208 and miR-499) for the in vitro induction of direct cell reprogramming of fibroblasts to cardiomyocytes [19]. Furthermore, reprogramming efficiency was also shown to be improved by modulators of epigenetic-related enzymes, such as DNA methyltransferases [20].

Despite all these advances, screenings for genes that regulate the cell fate towards a cardiovascular cell fate continued and eventually introduced the idea of a “master regulator” that plays a key role in the early development of the vessels and the heart [21,22]. In ECs, for example, Etv2 was shown to be quite promising, with several groups using it to convert human amniotic cells or fibroblasts into ECs [23-25]. At the same time, it is long known that inhibiting or activating certain pathways will change the cell fate. Harding et al. [26] proved that the MAPK and the PI3K pathways are crucial to

EC differentiation from iPSCs with high purities (94%-97% CD31+ and 78%-83% VE-cadherin+) in 8 days without cell sorting. Cases like this showcase the importance of epigenetic modulation, with subsequent stabilisation of this state, so that it can produce functional cells.

### STABILISING THE CELL FATE

Attempting to stabilise the cell fate in the reprogramming cells led to the use of small molecules either during or after differentiation. The use of recombinant proteins to enhance the activity of certain pathways is widely used, with the VEGF pathway being one of the most important ones due to its significant role in ECs; even a small amount of VEGFA supplement in the culture media can lead to the significant enhancement of EC function and morphology [27-29]. Currently, reprogramming with small molecules is investigated with breakthroughs in neuron [30] and cardiac [31] generation. Cases like this are distinctive and their integration into the reprogramming technology will give rise to protocols that have higher efficiency and, in some cases, are shorter in duration.

### CHALLENGES AND A LOOK INTO THE FUTURE

In animal embryos, cells transition from a multi potential state, with the capacity to adopt multiple fates, into an irreversible, committed state of differentiation [32]. This is a phrase that was accepted as a universal truth for many years. Being able to rewind the clock on a committed cell line by manipulating the microenvironment and its genetic makeup, contradicts its finality and allows us to look past that: 1. Investigating the molecular mechanisms during differentiation is the key to unlocking the epigenetic networks at work so that a usable vascular model can be created. 2. Further studies, including optimization of vascular reprogramming in human fibroblasts, are needed. As the demand is high for new regenerative therapies, the opportunities and the potential benefits of this direct reprogramming approach are significant. With this final thought two questions remain; which approach is better? What is the difference between the mechanisms involved in the two approaches? Maybe we are not any closer to answering these than we were 30 years ago but studying how the epigenetic and metabolic profile of the cells change during differentiation from iPSCs to a committed cell type is certainly the key to discovering the missing piece of the puzzle of direct somatic reprogramming. The epigenetic changes are crucial in directing a different phenotype and mimicking the microenvironment of the target-cell will facilitate the transition. On this basis, the idea of in vivo reprogramming – an interesting sum of techniques, albeit still not proven safe [33-35] and its possible combination with in vitro re-modelling would create a model to study vascular regeneration universally.

## ACKNOWLEDGEMENT

This work was supported by Grants from BBSRC and the British Heart Foundation.

## REFERENCES

1. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126: 663-676.
2. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 131: 861-872.
3. Chang MY, Kim D, Kim CH, Kang HC, Yang E, et al. (2010) Direct reprogramming of rat neural precursor cells and fibroblasts into pluripotent stem cells. *PLoS One* 5: e9838.
4. Mitalipov S, Kuo HC, Byrne J, Clepper L, Meisner L, et al. (2006) Isolation and characterization of novel rhesus monkey embryonic stem cell lines. *Stem Cells* 24: 2177-2186.
5. Davis RL, Weintraub H, Lassar AB (1987) Expression of a single transfected cDNA converts fibroblasts to myoblasts. *Cell* 51: 987-1000.
6. Graf T (2011) Historical origins of transdifferentiation and reprogramming. *Cell Stem Cell* 9: 504-516.
7. Kim J, Efe JA, Zhu S, Talantova M, Yuan X, et al. (2011) Direct reprogramming of mouse fibroblasts to neural progenitors. *Proc Natl Acad Sci U S A* 108: 7838-7843.
8. Margariti A, Winkler B, Karamariti E, Zampetaki A, Tsai TN, et al. (2012) Direct reprogramming of fibroblasts into endothelial cells capable of angiogenesis and reendothelialization in tissue-engineered vessels. *Proc Natl Acad Sci U S A* 109: 13793-13798.
9. Karamariti E, Margariti A, Winkler B, Wang X, Hong X, et al. (2013) Smooth muscle cells differentiated from reprogrammed embryonic lung fibroblasts through DKK3 signaling are potent for tissue engineering of vascular grafts. *Circ Res* 112: 1433-1443.
10. Collado MS, Cole BK, Figler RA, Lawson M, Manka D, et al. (2017) Exposure of Induced pluripotent stem cell-derived vascular endothelial and smooth muscle cells in coculture to hemodynamics induces primary vascular cell-like phenotypes. *Stem Cells Transl Med* 6: 1673-1683.
11. Hong X, Margariti A, Le Bras A, Jacquet L, Kong W, et al. (2017) Transdifferentiated human vascular smooth muscle cells are a new potential cell source for endothelial regeneration. *Sci Rep* 7: 5590.
12. Kelaini S, Cochrane A, Margariti A (2014) Direct reprogramming of adult cells: avoiding the pluripotent state. *Stem Cells Cloning* 7: 19-29.
13. Li J, Huang NF, Zou J, Laurent TJ, Lee JC, et al. (2013) Conversion of human fibroblasts to functional endothelial cells by defined factors. *Arterioscler Thromb Vasc Biol* 33: 1366-1375.
14. Wang H, Cao N, Spencer CI, Nie B, Ma T, et al. (2014) Small molecules enable cardiac reprogramming of mouse fibroblasts with a single factor, Oct4. *Cell Rep* 6: 951-960.
15. Montserrat N, Nivet E, Sancho-Martinez I, Hishida T, Kumar S, et al. (2013) Reprogramming of human fibroblasts to pluripotency with lineage specifiers. *Cell Stem Cell* 13: 341-350.
16. Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, et al. (2010) Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. *Cell* 142: 375-386.
17. Han JK, Chang SH, Cho HJ, Choi SB, Ahn HS, et al. (2014) Direct conversion of adult skin fibroblasts to endothelial cells by defined factors. *Circulation* 130: 1168-1178.
18. Addis RC, Ifkovits JL, Pinto F, Kellam LD, Estes P, et al. (2013) Optimization of direct fibroblast reprogramming to cardiomyocytes using calcium activity as a functional measure of success. *J Mol Cell Cardiol* 60: 97-106.
19. Jayawardena TM, Egemnazarov B, Finch EA, Zhang L, Payne JA, et al. (2012) MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. *Circ Res* 110: 1465-1473.
20. Mikkelsen TS, Hanna J, Zhang X, Ku M, Wernig M, et al. (2008) Dissecting direct reprogramming through integrative genomic analysis. *Nature* 454: 49-55.
21. Protze S, Khattak S, Poulet C, Lindemann D, Tanaka EM, et al. (2012) A new approach to transcription factor screening for reprogramming of fibroblasts to cardiomyocyte-like cells. *J Mol Cell Cardiol* 53:323-332.
22. Lee S, Kim JE, Johnson BA, Andukuri A, Yoon YS (2017) Direct reprogramming into endothelial cells: a new source for vascular regeneration. *Regen Med* 12: 317-320.
23. Van Pham P, Vu NB, Nguyen HT, Huynh OT, Truong MT (2016) Significant improvement of direct reprogramming efficacy of fibroblasts into progenitor endothelial cells by ETV2 and hypoxia. *Stem Cell Res Ther* 7: 104.

24. Ginsberg M, Schachterle W, Shido K, Rafii S (2015) Direct conversion of human amniotic cells into endothelial cells without transitioning through a pluripotent state. *Nat Protoc* 10: 1975-1985.
25. Wong WT, Cooke JP (2016) Therapeutic transdifferentiation of human fibroblasts into endothelial cells using forced expression of lineage-specific transcription factors. *J Tissue Eng* 7: 2041731416628329.
26. Harding A, Cortez-Toledo E, Magner NL, Beegle JR, Coleal-Bergum DP, et al. (2017) Highly efficient differentiation of endothelial cells from pluripotent stem cells requires the MAPK and the PI3K pathways. *Stem Cells* 35: 909-919.
27. Shibuya M (2011) Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: A crucial target for anti- and pro-angiogenic therapies. *Genes Cancer* 2: 1097-1105.
28. Eichmann A, Simons M (2012) VEGF signaling inside vascular endothelial cells and beyond. *Curr Opin Cell Biol* 24: 188-193.
29. Abhinand CS, Raju R, Soumya SJ, Arya PS, Sudhakaran PR (2016) VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis. *J Cell Commun Signal* 10: 347-354.
30. Babos K, Ichida JK (2015) Small molecules take a big step by converting fibroblasts into neurons. *Cell Stem Cell* 17: 127-129.
31. Cao N, Huang Y, Zheng J, Spencer CI, Zhang Y, et al. (2016) Conversion of human fibroblasts into functional cardiomyocytes by small molecules. *Science* 352: 1216-1220.
32. Spickard EA, Joshi PM, Rothman JH (2018) The multipotency-to-commitment transition in *Caenorhabditis elegans*-implications for reprogramming from cells to organs. *FEBS Lett* 592: 838-851.
33. Xu H, Yi BA, Chien KR (2012) In vivo reprogramming for heart disease. *Cell Res* 22: 1521-1523.
34. Srivastava D, Dewitt N (2016) In vivo cellular reprogramming: The next generation. *Cell* 166: 1386-1396.
35. Sadahiro T, Yamanaka S, Ieda M (2015) Direct cardiac reprogramming: Progress and challenges in basic biology and clinical applications. *Circ Res* 116: 1378-1391.